NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade

Rhea-AI Filing Summary

NovoCure Ltd’s Chief Human Resources Officer, Michal Nath Puri, reported an automatic sale of 1,441 Ordinary Shares. The shares were sold on February 27, 2026 in open-market trades at a weighted average price of about $13.66 per share, within a range of $13.45 to $13.97.

According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units, not a discretionary trade. After this sale, Puri directly held 162,322 Ordinary Shares of NovoCure.

Insider Trade Summary

Net Seller: 1,441 shares ($19,690)

Net Sell 1 txn

Insider Puri Michal Nath

Role Chief Human Resources Officer

Sold 1,441 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,441	$13.6638	$20K

Holdings After Transaction: Ordinary Shares — 162,322 shares (Direct)

Footnotes (1)

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puri Michal Nath

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/27/2026		S		1,441(1)	D	$13.6638(2)	162,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Puri, Michal Nath	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NovoCure (NVCR) report for Michal Nath Puri?

NovoCure reported that Chief Human Resources Officer Michal Nath Puri sold 1,441 Ordinary Shares. The transaction was an automatic sale to cover tax withholding obligations related to vesting Restricted Stock Units, rather than a discretionary decision to reduce ownership.

At what price were the NovoCure (NVCR) shares sold in this Form 4?

The shares were sold at a weighted average price of approximately $13.66 per share. Individual trades occurred in a price range between $13.45 and $13.97, according to the Form 4’s footnote describing the execution details.

Why did NovoCure’s CHRO sell 1,441 shares in this filing?

The sale was required to cover tax withholding obligations from vesting Restricted Stock Units. NovoCure’s equity award agreement mandates a “sell to cover” transaction, meaning these shares were sold automatically for taxes rather than as a voluntary portfolio adjustment.

How many NovoCure (NVCR) shares does Michal Nath Puri hold after the transaction?

After the tax-related sale of 1,441 Ordinary Shares, Michal Nath Puri directly owned 162,322 NovoCure Ordinary Shares. This post-transaction holding figure is disclosed in the Form 4 as the total shares beneficially owned following the reported trade.

Was the NovoCure (NVCR) insider trade a discretionary sale by the CHRO?

No, the filing specifies the transaction did not represent a discretionary trade. It states the sale was mandated under NovoCure’s equity incentive plans to fund tax withholding via a required “sell to cover” transaction tied to Restricted Stock Unit vesting.